S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   321.05 (-0.22%)
AAPL   164.88 (-0.28%)
MSFT   280.53 (-0.84%)
META   170.47 (+2.01%)
GOOGL   117.41 (-0.05%)
AMZN   139.63 (-0.83%)
TSLA   871.50 (+0.81%)
NVDA   178.14 (-6.19%)
NIO   20.18 (-0.20%)
BABA   90.95 (-1.74%)
AMD   100.05 (-2.21%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.19 (+1.12%)
F   15.78 (+3.14%)
DIS   109.09 (+2.31%)
AMC   23.96 (+8.03%)
PYPL   96.33 (+1.06%)
PFE   49.33 (+0.12%)
NFLX   233.37 (+2.91%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   321.05 (-0.22%)
AAPL   164.88 (-0.28%)
MSFT   280.53 (-0.84%)
META   170.47 (+2.01%)
GOOGL   117.41 (-0.05%)
AMZN   139.63 (-0.83%)
TSLA   871.50 (+0.81%)
NVDA   178.14 (-6.19%)
NIO   20.18 (-0.20%)
BABA   90.95 (-1.74%)
AMD   100.05 (-2.21%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.19 (+1.12%)
F   15.78 (+3.14%)
DIS   109.09 (+2.31%)
AMC   23.96 (+8.03%)
PYPL   96.33 (+1.06%)
PFE   49.33 (+0.12%)
NFLX   233.37 (+2.91%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   321.05 (-0.22%)
AAPL   164.88 (-0.28%)
MSFT   280.53 (-0.84%)
META   170.47 (+2.01%)
GOOGL   117.41 (-0.05%)
AMZN   139.63 (-0.83%)
TSLA   871.50 (+0.81%)
NVDA   178.14 (-6.19%)
NIO   20.18 (-0.20%)
BABA   90.95 (-1.74%)
AMD   100.05 (-2.21%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.19 (+1.12%)
F   15.78 (+3.14%)
DIS   109.09 (+2.31%)
AMC   23.96 (+8.03%)
PYPL   96.33 (+1.06%)
PFE   49.33 (+0.12%)
NFLX   233.37 (+2.91%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   321.05 (-0.22%)
AAPL   164.88 (-0.28%)
MSFT   280.53 (-0.84%)
META   170.47 (+2.01%)
GOOGL   117.41 (-0.05%)
AMZN   139.63 (-0.83%)
TSLA   871.50 (+0.81%)
NVDA   178.14 (-6.19%)
NIO   20.18 (-0.20%)
BABA   90.95 (-1.74%)
AMD   100.05 (-2.21%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.19 (+1.12%)
F   15.78 (+3.14%)
DIS   109.09 (+2.31%)
AMC   23.96 (+8.03%)
PYPL   96.33 (+1.06%)
PFE   49.33 (+0.12%)
NFLX   233.37 (+2.91%)

PetVivo Holdings Is A Growth Stock Worth a Look

PetVivo Holdings Is A Growth Stock Worth a Look

PetVivo Enters Into A Definitive Agreement For Lead Therapy

The market conditions aren’t screaming “buy growth stocks now” at us but that doesn’t mean all growth stocks, like PetVivo (OTCMKTS: PETV), are or will suffer the same afflictions. PetVivo caught our attention because of two things; its market and a new deal to market its lead therapy. PetVivo is a biomedical devices company focused on animal health which is a rapidly growing segment of the American economy. The company is focused on “equine athletes and companion animals” and is currently marketing a single therapy called Spryng. Spryng is an osteo-cushion made from thousands of tiny microcells and is being used to replace missing cartilage and provide a scaffolding for other types of tissue repairs.

The agreement is with MWI Animal Health, a nationwide distributor of animal health products to veterinarians and retail businesses. The agreement is for MWI Animal Health to inventory, market, and promote Spryng to its customer base which we view as incredibly bullish. MWI Animal Health is a subsidiary of AmerisourceBergen which is itself a leading distributor of medical and pharmaceutical products in America and Internationally. The deal should not only boost sales of Spryng but also opens the door for new product lines as they become available. PetVivi is boasting a pipeline of 17 devices that should begin hitting the shelves 

At Least One Analyst Sees An Opportunity In PetVivo

Osteo-care is a multi-billion dollar opportunity within the pet care industry. The estimated value of US veterinary care and devices is estimated at $11 billion in 2021 with high-single-digit growth in the time since and the same forecast for the foreseeable future. Within that, it is estimated that a quarter of all dogs and 50% or more of all horses suffer from some form of joint or osteoarthritis condition that could be treated with Spryng and/or one of the many pipeline products in development. 


And there is at least one analyst who views this stock as an opportunity although we think the number will grow once revenue and earnings are established. That analyst is ThinkEquity which rates the stock a Buy and gives a price target of $7. That target was set at the end of 2021 and implies about 285% of upside for the stock. In our view, the $7 target is a bit low but understandable given the age of the business and budding support from the institutions. The institutional activity has been mixed over the past year and is net-bearish but there are a few things to consider. The first is the institutions hold about 14% of the stock, the second is the selling was done in Q1 by a single firm, and the third is that Q2 activity turned bullish. The latest transaction is by Vanguard Group which upped its holdings to 2.31% of the float. 

The Technical Outlook: PetVivo Bottoms As Sales Begin 

PetVivo began sales of Spryng in the 2nd quarter of fiscal 2022 and the price action has been trying hard to reverse course ever since. The FY Sales came in well below expectations but this is due to a slower-than-expected roll-out of Spryng. Assuming the deal with MWI Animal Health works out as expected, we see revenue ramping significantly as soon as the current fiscal quarter and then growing along with the broader pet care market. Turning to the chart, the stock is bottomed at the $1.25 level and is now confirming support at a higher level. The new support is at the $1.50 level and could result in a rebound up to the $2.50 to $2.75 level. If these levels can be broken we see the stock moving up into the $4.00 to $5.00 range by the end of the year. 

PetVivo Holdings Is A Growth Stock You Might Want To Buy

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
PetVivo (PETV)
1.9425 of 5 stars
$2.20+1.9%N/A-3.55Buy$7.00
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in PetVivo right now?

Before you consider PetVivo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PetVivo wasn't on the list.

While PetVivo currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastFind Investing Opportunities For The Rest of 2022

Today, Kate’s guest is Rhys Williams, chief investment officer for the Opportunistic All Cap Equity, a long-short strategy at Spouting Rock Asset Management.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.